Abundance Wealth Counselors Has $345,000 Stock Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Abundance Wealth Counselors lifted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 10.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,529 shares of the company’s stock after purchasing an additional 528 shares during the quarter. Abundance Wealth Counselors’ holdings in TransMedics Group were worth $345,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in TMDX. State of Alaska Department of Revenue bought a new stake in shares of TransMedics Group in the third quarter worth $2,560,000. Charles Schwab Investment Management Inc. raised its position in TransMedics Group by 2.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock worth $42,656,000 after acquiring an additional 6,634 shares in the last quarter. Zacks Investment Management acquired a new position in shares of TransMedics Group during the 3rd quarter worth about $1,607,000. Vaughan Nelson Investment Management L.P. raised its holdings in shares of TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after purchasing an additional 64,872 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Insider Activity

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now directly owns 20,843 shares in the company, valued at $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

TMDX has been the subject of a number of recent analyst reports. Canaccord Genuity Group cut their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price target (down from $116.00) on shares of TransMedics Group in a research report on Tuesday, December 17th. TD Cowen cut their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Robert W. Baird dropped their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Finally, Piper Sandler reduced their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Price Performance

TMDX stock opened at $67.55 on Friday. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a market capitalization of $2.27 billion, a P/E ratio of 71.86 and a beta of 2.12. The company has a fifty day moving average price of $67.28 and a 200-day moving average price of $112.27.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.